Abstract

Attachment proteins from the surface of eukaryotic cells, bacteria and viruses are critical receptors in cell adhesion or signaling and are primary targets for the development of vaccines and therapeutic antibodies. It is proposed that the ligand-binding pocket in receptor proteins can shift between inactive and active conformations with weak and strong ligand-binding capability, respectively. Here, using monoclonal antibodies against a vaccine target protein - fimbrial adhesin FimH of uropathogenic Escherichia coli, we demonstrate that unusually strong receptor inhibition can be achieved by antibody that binds within the binding pocket and displaces the ligand in a non-competitive way. The non-competitive antibody binds to a loop that interacts with the ligand in the active conformation of the pocket but is shifted away from ligand in the inactive conformation. We refer to this as a parasteric inhibition, where the inhibitor binds adjacent to the ligand in the binding pocket. We showed that the receptor-blocking mechanism of parasteric antibody differs from that of orthosteric inhibition, where the inhibitor replaces the ligand or allosteric inhibition where the inhibitor binds at a site distant from the ligand, and is very potent in blocking bacterial adhesion, dissolving surface-adherent biofilms and protecting mice from urinary bladder infection.

Highlights

  • Receptor-ligand interactions are among the most basic biological phenomena involved in cell signaling, adhesion and pathogen attachment

  • Parasteric Inactivation of FimH Binding Pocket sterically interfere with ligand binding and block receptor function via a competitive mechanism

  • Using monoclonal antibodies specific for the mannose-binding Escherichia coli adhesin, FimH, we demonstrate that the binding site epitopes allow for non-competitive inhibition that is more effective than orthosteric blocking

Read more

Summary

Introduction

Receptor-ligand interactions are among the most basic biological phenomena involved in cell signaling, adhesion and pathogen attachment. Orthosteric inhibitors directly compete with ligands for the binding pocket and, their receptor-inhibitory activity is of a competitive nature [1]. Allosteric inhibitors exert their effects via interaction with a site that is separate from the ligand-binding pocket and accomplish the inhibition in a non-competitive manner [2]. This antibody exerts noncompetitive inhibition, but like an orthosteric inhibitor, it binds within the ligand-binding pocket. Unlike the latter, it forces the conversion of the binding pocket to an open, inactive conformation, even when the pocket is occupied by the ligand mannose

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.